Table 2 Changes in symptom scores after proton pump inhibitor administration.

From: Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: a prospective multicenter study

Variable

Baseline

Week 4

P-value (vs. baseline)

Week 8

P-value (vs. baseline)

P-value (vs. week 4)

PAGI-SYM (0–5)

Heartburn/regurgitation

 Heartburn

1.85 ± 1.43

0.65 ± 0.93

 < 0.001

0.54 ± 0.80

 < 0.001

0.381

 Regurgitation

2.18 ± 1.45

0.73 ± 0.93

 < 0.001

0.50 ± 0.38

 < 0.001

0.035

Nausea/vomiting

0.97 ± 1.09

0.32 ± 0.52

 < 0.001

0.23 ± 0.66

 < 0.001

0.396

Early satiety

1.49 ± 1.03

0.84 ± 0.72

 < 0.001

0.59 ± 0.64

 < 0.001

0.001

Bloating

1.35 ± 1.28

0.74 ± 0.91

 < 0.001

0.48 ± 0.85

 < 0.001

0.018

Upper abdominal pain

1.72 ± 1.46

0.76 ± 1.13

 < 0.001

0.56 ± 0.85

 < 0.001

0.166

Lower abdominal pain

0.85 ± 1.21

0.60 ± 1.00

0.069

0.45 ± 0.74

0.004

0.107

HAD (0–3)

 Anxiety

0.76 ± 0.49

0.57 ± 0.42

 < 0.001

0.50 ± 0.38

 < 0.001

0.038

 Depression

0.81 ± 0.44

0.67 ± 0.46

0.003

0.58 ± 0.44

 < 0.001

0.019

Adherence rate (%)

 

97.5 ± 5.2

 

96.8 ± 5.8

 

0.435

  1. PAGI-SYM, HAD, and adherence rate were presented as mean with standard deviation.
  2. Adherence rate was defined as the number of drugs taken divided by the number of drugs to be taken.
  3. PAGI-SYM, patient assessment of upper gastrointestinal symptom severity index; HAD, hospital anxiety and depression scale.
Back to article page